The reports represented 25 more cases than Britain's medicines regulator had previously received, going some way toward addressing a mystery that has hung over safety concerns about the vaccine: why Britain had not observed the same phenomenon that has been seen in continental Europe, driving countries including France, Germany and Sweden to stop giving the shot to younger people, who are believed to be at higher risk from the rare clotting events.
There have been seven deaths among the 30 cases. "There is substantial uncertainty about the benefit of providing AstraZeneca COVID-19 vaccines to adults under 55 given the potential risks", Canada's National Advisory Committee on Immunization said.
Prosecutors have opened an investigation into that case while emphasising that no link had been established yet with the jab.
"Clearly more work needs to be done, but I think the evidence is shifting more towards it being causally related at the moment".
The MHRA urged people to continue taking the AstraZeneca coronavirus vaccine.
"It is a complaint "against X", because we have no element against a named person for manslaughter", said Boittin, adding that this "classification can evolve" as the case develops.
Germany is suspending use of the AstraZeneca vaccine for people aged under 60 due to fears of a link with rare blood clots.
Reports of unusual blood clots among AstraZeneca recipients have led some regulators to recommend restrictions on the jab, or the groups of people that can receive it.
However, Australia's Therapeutic Goods Administration and the European Medicines Agency continue to back the rollout of the AstraZeneca vaccine. The risk associated with this type of blood clot is "very small", it added.
The 30 reports of thrombosis, submitted by doctors or members of the public via a government website, came after 18.1 million doses of the vaccine had been administered to people in the country.
"The benefits in preventing a COVID-19 infection and its complications continue to outweigh any risks and the public should continue to get their vaccine when invited to do so", June Raine, MHRA chief executive, told United Kingdom broadcaster the BBC.
Elaborating, Dr Noor Azmi, who is also the Bagan Serai Member of Parliament, said the AstraZeneca vaccine, produced from a viral vector by placing weak virus with protein to stimulate the human body similar to other vaccines, was expected to arrive in Malaysia in May.
Earlier we spoke to Professor of Public Health Linda Bauld and started by asking her about the relative risks of getting a blood clot from the vaccine.
"The MHRA is still consistently saying there's no cause for concern and that is absolutely the message to people".
She added: "It doesn't look from the behavioural response, the surveys I've seen, that it's affecting uptake in the United Kingdom and that's really important".